EVENT REGISTRATION Join free Rezdiffra Real Voices events today

Live events and virtual webinars are hosted by nurse educators and
Rezdiffra Real Voices Patient Ambassadors. You can ask questions, get support, and
hear personal stories about living with NASH with liver scarring.*

*Moderate to advanced liver scarring without cirrhosis.

EVENT REGISTRATION Join free Rezdiffra Real Voices events today

*Live events and virtual webinars are hosted by nurse educators and
Rezdiffra Real Voices Patient Ambassadors. You can ask questions, get support, and
hear personal stories about living with NASH with liver scarring.*

*Moderate to advanced liver scarring without cirrhosis.

You’re all set !

Thank you for registering! See your confirmation below and add to your calendar.

You have registered for:

Finding Support icon

Finding Support

June 12, 7 PM ET

Add to calendar:
Coping With Chronic Disease icon

Coping With Chronic Disease

June 26, 6 PM ET

Add to calendar:
Finding Support icon

Finding Support

July 15, 6:30 PM ET

Add to calendar:
Shared Decision-Making icon

Shared Decision-Making

July 31, 7 PM ET

Add to calendar:

These programs are not intended to be medical advice and do not take the place of discussions with your healthcare team. Nurse educators and Patient Ambassadors are speaking on behalf of Madrigal and have been compensated for their participation.

In the meantime, review the links below for additional information

magnifying glass icon

Do you know if you have scarring? 

Testing is the only way to find out. Ask your liver specialist about testing for NASH with liver scarring today.

Learn more
shield icon

Manage your NASH

Learn more about Rezdiffra, a prescription pill taken once per day for adults with NASH with moderate to advanced liver scarring without cirrhosis, along with diet and exercise.  

Act Now
location icon

Support every step of the way

Check out Rezdiffra resources for more information,
including a doctor discussion guide and information on
advocacy groups.

Learn more
mail icon

Share your story  

Your experience is powerful—and your story may play an important role in shaping someone else’s. Share your journey living with noncirrhotic NASH with liver scarring* and taking Rezdiffra, and inspire others to take the next step to help protect their liver.

Share here
NAFLD icon

Learn more about NASH

Your fatty liver disease may already be NASH with liver scarring. Want to know how you can find out?

Learn more
shield icon

Show up for your liver

Sign up to stay informed about your disease state and how Rezdiffra may be able to help.

Explore today
magnifying glass icon

Find a specialist who can help

Taking the first step is always hard—but connecting with a specialist who can arrange testing for liver scarring can help make it a lot easier.

Get started
question icon

Learn more about NASH and fatty liver disease

Knowledge can be powerful. That’s why knowing which options are available for noncirrhotic NASH with moderate to advanced liver scarring can help get a handle on the health of your liver.

Learn more

Download the Doctor Discussion Guide

Important Safety Information and Indication

Before you take Rezdiffra, tell your healthcare provider about all of your medical conditions, including if you:

  • have any liver problems other than MASH.
  • have gallbladder problems or have been told you have gallbladder problems, including gallstones.
  • are pregnant or plan to become pregnant. It is not known if Rezdiffra will harm your unborn baby.
  • are breastfeeding or plan to breastfeed. It is not known if Rezdiffra passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you take Rezdiffra.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

  • Rezdiffra and other medicines may affect each other, causing side effects. Rezdiffra may affect the way other medicines work, and other medicines may affect how Rezdiffra works.
  • Especially tell your healthcare provider if you take medicines that contain gemfibrozil to help lower your triglycerides, or cyclosporine to suppress your immune system, because Rezdiffra is not recommended in patients taking these medicines.
  • Tell your healthcare provider if you are taking medicines such as clopidogrel to thin your blood or statin medicines to help lower your cholesterol.
  • Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

What are the possible side effects of Rezdiffra?

Rezdiffra may cause serious side effects, including:

  • liver injury (hepatotoxicity). Stop taking Rezdiffra and call your healthcare provider right away if you develop the following signs or symptoms of hepatotoxicity: tiredness, nausea, vomiting, fever, rash, your skin or the white part of your eyes turns yellow (jaundice), or stomach pain/tenderness.
  • gallbladder problems. Gallbladder problems such as gallstones, or inflammation of the gallbladder, or inflammation of the pancreas from gallstones can occur with MASH and may occur if you take Rezdiffra. Call your healthcare provider right away if you develop any signs or symptoms of these conditions, including nausea, vomiting, fever, or pain in your stomach area (abdomen) that is severe and will not go away. The pain may be felt going from your abdomen to your back and the pain may happen with or without vomiting.

The most common side effects of Rezdiffra include diarrhea, nausea, itching, stomach pain, vomiting, dizziness, and constipation.

These are not all the possible side effects of Rezdiffra. For more information, ask your healthcare provider or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Madrigal Pharmaceuticals, Inc. at 1-800-905-0324.

What is Rezdiffra?

Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with metabolic dysfunction–associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver.

This indication is approved based on improvement of MASH and liver scarring (fibrosis). There are ongoing studies to confirm the clinical benefit of Rezdiffra.

Please see the accompanying full Prescribing Information, including Patient Information, for Rezdiffra.